Anna Berkenblit named chief scientific and medical officer of PanCAN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Anna Berkenblit, a clinical oncologist and drug developer, was named the first-ever chief scientific and medical officer of the Pancreatic Cancer Action Network. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login